Pacific Edge Limited (NZE:PEB)
New Zealand · Delayed Price · Currency is NZD | Market Cap | 328.16M +344.2% |
| Revenue (ttm) | 13.60M -44.9% |
| Net Income | -35.78M |
| EPS | -0.04 |
| Shares Out | 1.17B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 937,348 |
| Open | 0.2600 |
| Previous Close | 0.2650 |
| Day's Range | 0.2600 - 0.2800 |
| 52-Week Range | 0.0820 - 0.3400 |
| Beta | 0.74 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 24, 2026 |
About Pacific Edge
Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; and Cxbladder Monitor, a non-inva... [Read more]
Financial Performance
In fiscal year 2026, Pacific Edge's revenue was 13.60 million, a decrease of -40.22% compared to the previous year's 22.75 million. Losses were -35.78 million, 19.5% more than in 2025.
Financial StatementsNews
Pacific Edge Earnings Call Transcript: H2 2026
FY 2026 saw revenue fall 47% and a net loss of NZD 35.8 million due to Medicare non-coverage, but recent draft Medicare coverage for Triage and Triage Plus, a successful NZD 25.4 million capital raise, and APAC growth position the business for recovery and future profitability.
Pacific Edge Slides: H2 2026
Pacific Edge has posted slides in relation to its H2 2026 quarterly earnings report, which was published on May 24, 2026.
Pacific Edge Earnings release: H2 2026
Pacific Edge released its H2 2026 earnings on May 24, 2026, summarizing the period's financial results.
Pacific Edge Annual report: H2 2026
Pacific Edge has published its H2 2026 annual report on May 24, 2026.
Fisher & Paykel downgrade drags NZX 50 lower as Pacific Edge jumps – Market close
Cancer tester Pacific Edge soared more than 54% on a key US Medicare draft ruling.
Pacific Edge Transcript: Investor update
Draft Medicare coverage for key tests is expected before September 2026, with claim-by-claim reimbursement targeted to drive interim revenue. Cash burn has been reduced, a NZD 24 million capital raise is underway, and commercial payer adoption is advancing, supported by strong clinical evidence and new pilot studies.
Pacific Edge Slides: Investor update
Pacific Edge has posted slides in relation to its latest quarterly earnings report, which was published on May 10, 2026.
Pacific Edge Press release: Investor update
Pacific Edge issued a press release on May 10, 2026, disclosing material business information to investors.
Pacific Edge Slides: Investor presentation
Pacific Edge has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
Pacific Edge Earnings Call Transcript: H1 2026
Revenue and test volumes declined sharply due to Medicare non-coverage, resulting in a $19.1M net loss and increased reliance on cash reserves. Strategic milestones include a price increase for Triage Plus and a key policy review by Novitas in early 2026, with recovery dependent on appeal outcomes.
Pacific Edge Quarterly report: H1 2026
Pacific Edge has published its H1 2026 quarterly earnings report on November 24, 2025.
Pacific Edge Slides: H1 2026
Pacific Edge has posted slides in relation to its H1 2026 quarterly earnings report, which was published on November 24, 2025.
Pacific Edge Transcript: AGM 2025
The meeting highlighted strategic progress with AUA guideline inclusion and a successful capital raise, despite the significant challenge of losing Medicare coverage. The board emphasized governance, risk management, and a pivot to commercial payers, with all resolutions passed by strong shareholder support.
Pacific Edge Slides: FY 2025
Pacific Edge has posted slides in relation to its FY 2025 quarterly earnings report, which was published on August 5, 2025.
Pacific Edge Earnings Call Transcript: H2 2025
Test volumes and revenue declined year-over-year, but commercial payer mix and sales efficiency improved. Major clinical guideline inclusion and a capital raise position the business for future growth, with Medicare coverage reinstatement a key catalyst.
Pacific Edge Slides: H2 2025
Pacific Edge has posted slides in relation to its H2 2025 quarterly earnings report, which was published on May 29, 2025.
Pacific Edge Annual report: H2 2025
Pacific Edge has published its H2 2025 annual report on May 29, 2025.